These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 8497873

  • 1. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols.
    Suthanthiran M, Haschemeyer RH, Riggio RR, Adubor C, Friedman GS, Cheigh JS, Wang JC, Fotino M, Stubenbord WT, Saal SD.
    Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873
    [Abstract] [Full Text] [Related]

  • 2. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients.
    Kasiske BL, Johnson HJ, Goerdt PJ, Heim-Duthoy KL, Rao VK, Dahl DC, Ney AL, Andersen RC, Jacobs DM, Odland MD.
    Am J Kidney Dis; 1997 Nov; 30(5):639-45. PubMed ID: 9370178
    [Abstract] [Full Text] [Related]

  • 4. The effects of delayed function on recipients of cadaver renal allografts. A study of 158 patients randomized to cyclosporine or ALG-azathioprine.
    Canafax DM, Torres A, Fryd DS, Heil JE, Strand MH, Ascher NL, Payne WD, Sutherland DE, Simmons RL, Najarian JS.
    Transplantation; 1986 Feb; 41(2):177-81. PubMed ID: 3511581
    [Abstract] [Full Text] [Related]

  • 5. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 6. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP, Johnson CP, Callaluce RD, Browne BJ, Zhu YR, Roza AM, Adams MB.
    Transplantation; 1993 Oct 15; 56(4):827-31. PubMed ID: 8212201
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
    Arbogast HP, Hoffmann JN, Illner WD, Hillebrand GF, Fischereder M, Jauch KW, Land W.
    Transplant Proc; 2009 Oct 15; 41(6):2529-32. PubMed ID: 19715968
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T.
    Transplantation; 1994 Feb 15; 57(3):377-84. PubMed ID: 8108873
    [Abstract] [Full Text] [Related]

  • 12. Effect of nifedipine on renal allograft function and survival beyond one year.
    Shin GT, Cheigh JS, Riggio RR, Suthanthiran M, Stubenbord WT, Serur D, Wang JC, Rubin AL, Stenzel KH.
    Clin Nephrol; 1997 Jan 15; 47(1):33-6. PubMed ID: 9021239
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
    Hong JC, Kahan BD.
    Transplantation; 2001 May 15; 71(9):1320-8. PubMed ID: 11397971
    [Abstract] [Full Text] [Related]

  • 16. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE, Fryd DS, Strand MH, Canafax DM, Ascher NL, Payne WD, Simmons RL, Najarian JS.
    Am J Kidney Dis; 1985 Jun 15; 5(6):318-27. PubMed ID: 3893106
    [Abstract] [Full Text] [Related]

  • 17. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Mestre M, Torras J, Alsina J.
    Am J Kidney Dis; 1992 Dec 15; 20(6):603-10. PubMed ID: 1462990
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM, Canafax DM, Gillingham KJ, Humar A, Pandian K, Kerr SR, Najarian JS, Matas AJ.
    Clin Transplant; 1997 Dec 15; 11(6):552-7. PubMed ID: 9408683
    [Abstract] [Full Text] [Related]

  • 20. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 15; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.